Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00044135
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2002-08-20
Brief Title:
A Safety Study to Evaluate 12 Weeks of Treatment with Clevudine in Patients Infected with Hepatitis B Virus
Sponsor:
Triangle Pharmaceuticals
Organization:
Triangle Pharmaceuticals
Study Overview
Official Title:
A Phase II Randomized Partially-Blinded Study to Evaluate the Safety Tolerability Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine 10 mg 30 mg or 50 mg QD in Patients Infected with Hepatitis B Virus
Status:
UNKNOWN
Status Verified Date:
2002-11
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate the safety and effectiveness of 12 weeks of treatment with clevudine at one of three doses in patients chronically infected with hepatitis B virus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: